Targeted therapy combined with cellular immunotherapy after lung cancer surgery further reduces the risk of recurrence

With the successive identification of oncogenic driver genes in lung cancer, the classification of lung cancer has been further refined from a simple histopathological classification to a molecular classification based on driver genes. EGFR is commonly found in lung adenocarcinoma.

The EGFR gene is a type of gene that expresses epidermal growth factor receptors, promoting normal cell division and proliferation under physiological conditions. However, in some cases, mutations in proto-oncogenes can lead to the development of tumors, with a higher incidence in non-smoking female lung adenocarcinoma. When it was discovered that EGFR mutations often occur in lung adenocarcinoma tumors, people began to consider how to inhibit tumor growth by targeting these mutations. Later, EGFR monoclonal antibodies, commonly known as "targeted drugs," were developed. Typically, EGFR mutations make lung adenocarcinoma more sensitive to specific targeted drugs.